According to global cancer observatory, around 19,292,789 new cancer cases were reported worldwide in 2020, with breast cancer, lung cancer, colorectum cancer, prostate cancer and stomach cancer being the most prevalent types.
Application of the Natural Killer Cells in Treatment of Critical Diseases
Increasing application of natural killer cells for the treatment of various disease including liver diseases, infections, cancer, among others is expected to drive the growth of global natural killer cells therapeutics market in the forecast period. In addition to this, the natural killer cells play a pivotal role in the immune surveillance of tumor. This in turn is leading to the widespread adoption of natural killer cells therapeutics across the world.
Rise in Awareness about Immunotherapies
The prevalence of cancer has increased worldwide over the years and the found at treatment options are not that efficient since a lot of instances of reoccurrence of tumours has been witnessed, arising the need for development of an effective and permanent treatment. Immunotherapies have gained much attention in recent years to treat different malignancies. Among all the immunotherapies, CAR –T cell therapies have been studied and were used but have various limitations that led to the development of natural killer (NK) cell therapies. Growing the awareness among the population about various immunotherapies and increase in research and development of bi-specific antibody for engaging natural killer cells to eliminate tumor cells are driving the global natural killer (NK) cell therapeutics market.
Download Free Sample Report
Market Segmentation
Market Players
Affimed N.V., Century Therapeutics, Inc., Celularity Inc., Cytovac A/S, Dragonfly Therapeutics, Inc., Fate Therapeutics, Inc., Gamida Cell Ltd., ImmunityBio, Inc., Innate Pharma SA , Nkarta, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited , VaxCell Biotherapeutics Co., Ltd., Acepodia Inc., Glycostem Therapeutics B.V., among others
| Attribute | Details |
| Base Year | 2021 |
| Historic Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · By Type · By Application · By End User · By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Turkey; Egypt |
| Key companies profiled | Affimed N.V., Century Therapeutics, Inc., Celularity Inc., Cytovac A/S, Dragonfly Therapeutics, Inc., Fate Therapeutics, Inc., Gamida Cell Ltd., ImmunityBio, Inc., Innate Pharma SA , Nkarta, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited , VaxCell Biotherapeutics Co., Ltd., Acepodia Inc., Glycostem Therapeutics B.V. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
